Oyen WJG - Search Results

1

[⁸⁹Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer.

van Helden EJ, Elias SG, Gerritse SL, van Es SC, Boon E, Huisman MC, van Grieken NCT, Dekker H, van Dongen GAMS, Vugts DJ, Boellaard R, van Herpen CML, de Vries EGE, Oyen WJG, Brouwers AH, Verheul HMW, Hoekstra OS, Menke-van der Houven van Oordt CW. van Helden EJ, et al. Among authors: oyen wjg. Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):849-859. doi: 10.1007/s00259-019-04555-6. Epub 2019 Nov 9. Eur J Nucl Med Mol Imaging. 2020. PMID: 31705176 Free PMC article.

2

Preclinical and clinical evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose.

Laverman P, Brouwers AH, Dams ET, Oyen WJ, Storm G, van Rooijen N, Corstens FH, Boerman OC. Laverman P, et al. J Pharmacol Exp Ther. 2000 Jun;293(3):996-1001. J Pharmacol Exp Ther. 2000. PMID: 10869403

3

Tc-99m-PEG-Liposomes for the evaluation of colitis in Crohn's disease.

Brouwers AH, De Jong DJ, Dams ET, Oyen WJ, Boerman OC, Laverman P, Naber TH, Storm G, Corstens FH. Brouwers AH, et al. J Drug Target. 2000;8(4):225-33. doi: 10.3109/10611860008997901. J Drug Target. 2000. PMID: 11144233 Clinical Trial.

4

A 99Tcm-labelled leukotriene B4 receptor antagonist for scintigraphic detection of infection in rabbits.

Brouwers AH, Laverman P, Boerman OC, Oyen WJ, Barrett JA, Harris TD, Edwards DS, Corstens FH. Brouwers AH, et al. Nucl Med Commun. 2000 Nov;21(11):1043-50. doi: 10.1097/00006231-200011000-00010. Nucl Med Commun. 2000. PMID: 11192710

5

Evaluation of (pre-)malignant colonic abnormalities: endoscopic validation of FDG-PET findings.

Drenth JP, Nagengast FM, Oyen WJ. Drenth JP, et al. Eur J Nucl Med. 2001 Dec;28(12):1766-9. doi: 10.1007/s002590100645. Epub 2001 Oct 19. Eur J Nucl Med. 2001. PMID: 11734913

6

131 I-cG250 monoclonal antibody immunoscintigraphy versus [18 F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study.

Brouwers AH, Dorr U, Lang O, Boerman OC, Oyen WJ, Steffens MG, Oosterwijk E, Mergenthaler HG, Bihl H, Corstens FH. Brouwers AH, et al. Nucl Med Commun. 2002 Mar;23(3):229-36. doi: 10.1097/00006231-200203000-00005. Nucl Med Commun. 2002. PMID: 11891480 Clinical Trial.

7

Fluorinated amino acids for tumour imaging with positron emission tomography.

Laverman P, Boerman OC, Corstens FH, Oyen WJ. Laverman P, et al. Eur J Nucl Med Mol Imaging. 2002 May;29(5):681-90. doi: 10.1007/s00259-001-0716-y. Epub 2002 Jan 11. Eur J Nucl Med Mol Imaging. 2002. PMID: 11976809 Review.

8

Re: Clinical role of f-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma.

Steffens MG, Mulders PF, Brouwers AH, Oyen WJ. Steffens MG, et al. J Urol. 2002 Nov;168(5):2127-8. doi: 10.1016/S0022-5347(05)64320-0. J Urol. 2002. PMID: 12394731 No abstract available.

9

PET-CT: a matter of opinion?

Jager PL, Slart RH, Corstens F, Oyen WJ, Hoekstra O, Teule J. Jager PL, et al. Eur J Nucl Med Mol Imaging. 2003 Mar;30(3):470-1; author reply 471. doi: 10.1007/s00259-002-1081-1. Epub 2003 Jan 8. Eur J Nucl Med Mol Imaging. 2003. PMID: 12634973 No abstract available.

10

Evaluation of Tc-99m-labeled glycoprotein IIb/IIIa receptor antagonist DMP444 SPECT in patients with infective endocarditis.

Brouwers FM, Oyen WJ, Boerman OC, Barrett JA, Verheugt FW, Corstens FH, Van der Meer JW. Brouwers FM, et al. Clin Nucl Med. 2003 Jun;28(6):480-4. doi: 10.1097/01.RLU.0000067508.82824.75. Clin Nucl Med. 2003. PMID: 12911097

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

687 results

Search Page

Filters